Measles vaccine

Measles vaccine protects against becoming infected with measles.[1] Nearly all of those who do not develop immunity after a single dose develop it after a second dose.[1] When rate of vaccination within a population is greater than 92%, outbreaks of measles typically no longer occur; however, they may occur again if the rate of vaccination decrease.[1] The vaccine's effectiveness lasts many years.[1] It is unclear if it becomes less effective over time.[1] The vaccine may also protect against measles if given within a couple of days after exposure to measles.[2][1][3]

Measles vaccine
A child is given a measles vaccine.
Vaccine description
TargetMeasles virus
Vaccine typeAttenuated
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa601176
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NY (what is this?)  (verify)

The vaccine is generally safe, even for those infected by HIV.[1][4] Most children do not experience any side effects;[5] those that do occur are usually mild, such as fever, rash, pain at the site of injection, and joint stiffness; and are short-lived.[1][5] Anaphylaxis has been documented in about 3.5–10 cases per million doses.[1] Rates of Guillain–Barré syndrome, autism and inflammatory bowel disease do not appear to be increased by measles vaccination.[1][6]

The vaccine is available both by itself and in combinations such as the MMR vaccine (a combination with the rubella vaccine and mumps vaccine)[1] or the MMRV vaccine (a combination of MMR with the chickenpox vaccine).[7][8][9] The measles vaccine is equally effective for preventing measles in all formulations, but side effects vary for different combinations.[1][10] The World Health Organization (WHO) recommends measles vaccine be given at nine months of age in areas of the world where the disease is common, or at twelve months where the disease is not common.[11][1] Measles vaccine is based on a live but weakened strain of measles.[1] It comes as a dried powder which is mixed with a specific liquid before being injected either just under the skin or into a muscle.[1] Verification that the vaccine was effective can be determined by blood tests.[1]

The measles vaccine was first introduced in 1963.[12] In that year, the Edmonston-B strain of measles virus was turned into a vaccine by John Enders and colleagues and licensed in the United States.[13][14] In 1968, an improved and even weaker measles vaccine was developed by Maurice Hilleman and colleagues, and began to be distributed, becoming the only measles vaccine used in the United States since 1968.[15][13][14] About 85% of children globally had received this vaccine as of 2013.[16] In 2015, at least 160 countries provided two doses in their routine immunization.[17] It is on the World Health Organization's List of Essential Medicines.[18] As outbreaks easily occur in under-vaccinated populations, non-prevalence of disease is seen as a test of sufficient vaccination within a population.[19][20]

Medical uses
Measles cases reported in the United States before and after introduction of the vaccine.
Measles cases reported in Canada before and after introduction of the vaccine. Between 1959 and 1968 measles was not nationally reportable, hence there are no data are this period.
Measles cases reported in England and Wales.

One dose is about 93% effective while two doses of the vaccine are about 97% effective at preventing measles.[4] Before the widespread use of the vaccine, measles was so common that infection was considered "as inevitable as death and taxes."[21] In the United States, reported cases of measles fell from 3 to 4 million with 400 to 500 deaths to tens of thousands per year following introduction of two measles vaccines in 1963 (both an inactivated and a live attenuated vaccine (Edmonston B strain) were licensed for use, see chart at right).[4][22] Increasing uptake of the vaccine following outbreaks in 1971 and 1977 brought this down to thousands of cases per year in the 1980s. An outbreak of almost 30,000 cases in 1990 led to a renewed push for vaccination and the addition of a second vaccine to the recommended schedule. No more than 220 cases were reported in any year from 1997 to 2013, and the disease was believed no longer endemic in the United States.[23][24][25] In 2014, 667 cases were reported.[26]

The benefits of measles vaccination in preventing illness, disability, and death have been well documented. Within the first 20 years of being licensed in the U.S., measles vaccination prevented an estimated 52 million cases of the disease, 17,400 cases of intellectual disability, and 5,200 deaths.[27] From 1999 to 2004 a strategy led by the WHO and UNICEF led to improvements in measles vaccination coverage that averted an estimated 1.4 million measles deaths worldwide.[28] The vaccine for measles led to the near-complete elimination of the disease in the United States and other developed countries.[29] While the vaccine is made with a live virus which can cause side effects, these are far fewer and less serious than the sickness and death caused by measles itself; side effects ranging from rashes to, rarely, convulsions, occur in a small percentage of recipients.[30]

Measles is common worldwide. Although it was declared eliminated from the U.S. in 2000, high rates of vaccination and excellent communication with those who refuse vaccination are needed to prevent outbreaks and sustain the elimination of measles.[31] Of the 66 cases of measles reported in the U.S. in 2005, slightly over half were attributable to one unvaccinated teenager who became infected during a visit to Romania.[32] This individual returned to a community with many unvaccinated children. The resulting outbreak infected 34 people, mostly children and virtually all unvaccinated; three of them were hospitalized. The public health response required making almost 5,000 phone calls as part of contact tracing, arranging and performing testing as needed, and arranging emergency vaccination for at-risk people who had had contact with this person.[31] Taxpayers and local healthcare organizations likely paid more than US$167,000 in direct costs to contain this one outbreak.[31] A major epidemic was averted due to high rates of vaccination in the surrounding communities.[31]

The vaccine has non specific effects such as preventing respiratory infections, that may be greater than those of measles prevention alone.[33] These benefits are greater when the vaccine is given before one year of age.[34] A high-titre vaccine resulted in worse outcomes in girls, and consequently is not recommended by the World Health Organization.[35]

Schedule

The World Health Organization (WHO) recommends two doses of vaccine for all children.[1] In countries with high risk of disease the first dose should be given around nine months of age.[1] Otherwise it can be given at twelve months of age.[1] The second dose should be given at least one month after the first dose.[1] This is often done at age 15 to 18 months.[1] After one dose at the age of nine months 85% are immune, while a dose at twelve months results in 95% immunity.[12]

In the United States, the Centers for Disease Control and Prevention (CDC) recommends that children aged six to eleven months traveling outside the United States receive their first dose of MMR vaccine before departure[36] and then receive two more doses; one at 12–15 months (12 months for children in high-risk areas) and the second as early as four weeks later.[37] Otherwise the first dose is typically given at 12–15 months and the second at 4–6 years.[37]

In the UK, the National Health Service (NHS) recommendation is for a first dose at around 13 months of age and the second at three years and four months old.[38][39]

In Canada, Health Canada recommends that children traveling outside North America should receive an MMR vaccine if they are aged six to 12 months. However, after the child is 12 months old they should receive two additional doses to ensure long-lasting protection.[40]

Adverse effects

Adverse effects associated with the MMR vaccine include fever, rash, injection site pain and, in rare cases, red or purple discolorations on the skin known as thrombocytopenic purpura, or seizures related to fever (febrile seizure).[41][42]

Numerous studies have found no relationship between MMR vaccine and autism.[43][44][45][42]

Contraindications

It is inadvisable for some people to receive the measles or MMR vaccine, including cases of:

  • Pregnancy: MMR vaccine and its components should not be given to pregnant women.[46] Women of childbearing age should check with their doctor about getting vaccinated prior to getting pregnant.[9]
  • HIV-infected children, who may receive measles vaccines if their CD4+ lymphocyte count is greater than 15%.[47]
  • Weakened immune system due to HIV/AIDS or certain medical treatments[9]
  • Having a parent or sibling with a history of immune problems[9]
  • Condition that makes a patient bruise or bleed easily[9]
  • Recent transfusion of blood or blood products[9]
  • Tuberculosis[9]
  • Receiving other vaccines in the past 4 weeks[9]
  • Moderate or severe illness. However, mild illness (e.g., common cold) is usually not contraindicated.[9]

History
Cases of measles and deaths per 100000, per year, in the United States over the 20th century

John Franklin Enders, who had shared the 1954 Nobel Prize in Medicine for work on the polio virus, sent Thomas C. Peebles to Fay School in Massachusetts, where an outbreak of measles was underway; Peebles was able to isolate the virus from blood samples and throat swabs, and was later able to cultivate the virus and show that the disease could be passed on to monkeys inoculated with the material he had collected.[29] Enders was able to use the cultivated virus to develop a measles vaccine in 1963 by attenuation through cultured chicken embryo fibroblasts of the material isolated by Peebles.[48][49]

In the late 1950s and early 1960s, nearly twice as many children died from measles as from polio.[50] The vaccine Enders developed was based on the Edmonston strain of attenuated live measles virus, which was named for 11-year-old David Edmonston, the Fay student from whom Peebles had taken the culture that led to the virus's cultivation.[51]

In the mid-20th century, measles was particularly devastating in West Africa, where child mortality rate was 50 percent before age 5, and the children were struck with the type of rash and other symptoms common prior to 1900 in England and other countries. The first trial of a live attenuated measles vaccine was undertaken in 1960 by the British paediatrician David Morley in a village near Ilesha, Nigeria;[52] in case he could be accused of exploiting the Nigerian population, Morley included his own four children in the study. The encouraging results led to a second study of about 450 children in the village and at the Wesley Guild Hospital in Ilesha.

Following another epidemic, a larger trial was undertaken in September and October 1962, in New York City with the assistance of the WHO: 131 children received the live Enders-attenuated Edmonston B strain plus gamma globulin, 130 children received a "further attenuated" vaccine without gamma globulin, and 173 children acted as control subjects for both groups. As also shown in the Nigerian trial, the trial confirmed that the "further attenuated" vaccine was superior to the Edmonston B vaccine, and caused significantly fewer instances of fever and diarrhea. 2,000 children in the area were vaccinated with the further-attenuated vaccine.[53][54]

Maurice Hilleman at Merck & Co., a pioneer in the development of vaccinations, developed an improved version of the measles vaccine in 1968 and subsequently the MMR vaccine in 1971, which vaccinates against measles, mumps and rubella in a single shot followed by a booster.[13][30][55] One form is called "Attenuvax".[56] The measles component of the MMR vaccine uses Attenuvax,[57] which is grown in a chick embryo cell culture using the Enders' attenuated Edmonston strain.[57] Following ACIP recommendations, Merck decided not to resume production of Attenuvax as standalone vaccine on 21 October 2009.[58]

A 2022 study in the American Economic Journal found that the measles vaccine uptake led to increases in income of 1.1 percent and positive effects on employment due to greater productivity by those who were vaccinated.[59]

Types
Mumps, measles and rubella combined vaccine (MMR vaccine)

Measles is seldom given as an individual vaccine and is often given in combination with rubella, mumps, or varicella (chickenpox) vaccines.[1] Below is the list of measles-containing vaccines:

Society and culture

Most health insurance plans in the United States cover the cost of vaccines, and Vaccines for Children Program may be able to help those who do not have coverage.[62] State law requires vaccinations for school children, but offer exemptions for medical reasons and sometimes for religious or philosophical reasons.[63] All fifty states require 2 doses of the MMR vaccine at the appropriate age.[64]

References
  1. World Health Organization (April 2017). "Measles vaccines: WHO position paper – April 2017" (PDF). Weekly Epidemiological Record. 92 (17): 205–27. hdl:10665/255377. PMID 28459148. Lay summary (PDF). {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
  2. "Measles Vaccination and Infection: Questions and Misconceptions". ASM.org. Retrieved 29 April 2022.
  3. "Measles". www.who.int. Retrieved 29 April 2022.
  4. "About Measles Vaccination | Vaccination and Immunizations | CDC". www.cdc.gov. 9 January 2020. Archived from the original on 27 April 2020. Retrieved 30 April 2020.
  5. CDC (2 August 2019). "Measles and the Vaccine (Shot)". Centers for Disease Control and Prevention. Archived from the original on 29 January 2020. Retrieved 30 April 2020.
  6. "Measles, Mumps, and Rubella (MMR) Vaccination | CDC". www.cdc.gov. 5 April 2021. Retrieved 29 April 2022.
  7. Mitchell D (2013). The essential guide to children's vaccines. New York: St. Martin's Press. p. 127. ISBN 9781466827509. Archived from the original on 8 September 2017.
  8. "ProQuad- measles, mumps, rubella and varicella virus vaccine live injection, powder, lyophilized, for suspension". DailyMed. 26 September 2019. Archived from the original on 6 April 2020. Retrieved 29 January 2020.
  9. "MMR Vaccination | What You Should Know | Measles, Mumps, Rubella | CDC". www.cdc.gov. 24 December 2019. Archived from the original on 26 April 2020. Retrieved 30 April 2020.
  10. "Information Sheet Observed Rate of Vaccine Reactions" (PDF). World Health Organization (WHO). Archived (PDF) from the original on 19 December 2019. Retrieved 1 December 2018.
  11. "MEASLES VACCINE - Essential drugs". medicalguidelines.msf.org. Retrieved 28 April 2022.
  12. Centers for Disease Control and Prevention (2014). CDC health information for international travel 2014 the yellow book. p. 250. ISBN 9780199948505. Archived from the original on 8 September 2017.
  13. CDC (5 November 2020). "History of Measles". Centers for Disease Control and Prevention. Retrieved 9 February 2021.
  14. "Measles History". U.S. Centers for Disease Control and Prevention (CDC). 5 February 2018. Archived from the original on 6 April 2020. Retrieved 28 January 2020. This article incorporates text from this source, which is in the public domain.
  15. Philadelphia, The Children's Hospital of (20 November 2014). "Vaccine History: Developments by Year". www.chop.edu. Retrieved 28 April 2022.
  16. "Measles Fact sheet N°286". World Health Organization (WHO). November 2014. Archived from the original on 3 February 2015. Retrieved 4 February 2015.
  17. "Immunization coverage". World Health Organization (WHO). Archived from the original on 13 July 2017. Retrieved 12 July 2017.
  18. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  19. "Measles". www.who.int. Retrieved 28 April 2022.
  20. Abramson B (2018). Vaccine, vaccination, and immunization law. Bloomberg Law. pp. 10–30. ISBN 9781682675830.
  21. Babbott FL, Gordon JE (September 1954). "Modern measles". The American Journal of the Medical Sciences. 228 (3): 334–61. doi:10.1097/00000441-195409000-00013. PMID 13197385.
  22. "Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP)". www.cdc.gov. Archived from the original on 15 May 2012. Retrieved 27 April 2020.
  23. Centers for Disease Control and Prevention (CDC) (1994). "Summary of notifiable diseases, United States, 1993". MMWR. Morbidity and Mortality Weekly Report. 42 (53): i–xvii, 1–73. PMID 9247368. Archived from the original on 9 March 2010.
  24. Centers for Disease Control and Prevention (CDC) (July 2007). "Summary of notifiable diseases, United States, 2007". MMWR. Morbidity and Mortality Weekly Report. 56 (53): 1–94. Archived from the original on 13 June 2018. Retrieved 10 September 2017.
  25. Wallace G, Leroy Z (2015). "Measles". In Hamborsky J, Kroger A, Wolfe S (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: Public Health Foundation. Archived from the original on 7 February 2015. Retrieved 30 April 2019.
  26. "Measles Cases and Outbreaks". Archived from the original on 13 February 2015. Retrieved 30 November 2018.
  27. Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR (October 1985). "Health impact of measles vaccination in the United States". Pediatrics. 76 (4): 524–32. doi:10.1542/peds.76.4.524. PMID 3931045. S2CID 6512947.
  28. Centers for Disease Control and Prevention (CDC) (March 2006). "Progress in reducing global measles deaths, 1999-2004". MMWR. Morbidity and Mortality Weekly Report. 55 (9): 247–9. PMID 16528234. Archived from the original on 16 October 2007.
  29. Martin D (4 August 2010). "Dr. Thomas C. Peebles, Who Identified Measles Virus, Dies at 89". The New York Times. Archived from the original on 6 April 2020. Retrieved 11 February 2017.
  30. Collins H (30 August 1999). "The Man Who Saved Your Life - Maurice R. Hilleman - Developer of Vaccines for Mumps and Pandemic Flu". The Philadelphia Inquirer. Archived from the original on 6 March 2009. Retrieved 28 January 2020.
  31. Parker AA, Staggs W, Dayan GH, Ortega-Sánchez IR, Rota PA, Lowe L, Boardman P, Teclaw R, Graves C, LeBaron CW (August 2006). "Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States". The New England Journal of Medicine. 355 (5): 447–55. doi:10.1056/NEJMoa060775. PMID 16885548.
  32. Centers for Disease Control and Prevention (CDC) (December 2006). "Measles--United States, 2005". MMWR. Morbidity and Mortality Weekly Report. 55 (50): 1348–51. PMID 17183226. Archived from the original on 13 March 2015.
  33. Mina, Michael J. (June 2017). "Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits". The Journal of Infection. 74 Suppl 1: S10–S17. doi:10.1016/S0163-4453(17)30185-8. ISSN 1532-2742. PMID 28646947.
  34. Lochlainn, Laura M. Nic; Gier, Brechje de; Maas, Nicoline van der; Binnendijk, Rob van; Strebel, Peter M.; Goodman, Tracey; Melker, Hester E. de; Moss, William J.; Hahné, Susan J. M. (1 November 2019). "Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis". The Lancet Infectious Diseases. 19 (11): 1246–1254. doi:10.1016/S1473-3099(19)30396-2. ISSN 1473-3099. PMC 6838663. PMID 31548081.
  35. Sankoh O, Welaga P, Debpuur C, Zandoh C, Gyaase S, Poma MA, Mutua MK, Hanifi SM, Martins C, Nebie E, Kagoné M, Emina JB, Aaby P (June 2014). "The non-specific effects of vaccines and other childhood interventions: the contribution of INDEPTH Health and Demographic Surveillance Systems". International Journal of Epidemiology. 43 (3): 645–53. doi:10.1093/ije/dyu101. PMC 4052142. PMID 24920644.
  36. "Vaccine (Shot) for Measles". Centers for Disease Control and Prevention (CDC). 2 August 2019. Archived from the original on 29 January 2020. Retrieved 29 January 2020. This article incorporates text from this source, which is in the public domain.
  37. "Birth-18 Years Immunization Schedule". Centers for Disease Control and Prevention (CDC). 5 February 2019. Archived from the original on 6 March 2016. Retrieved 29 January 2020. This article incorporates text from this source, which is in the public domain.
  38. "Measles". National Health Service UK. 20 October 2017. Archived from the original on 8 March 2019. Retrieved 11 March 2019.
  39. "MMR vaccine overview". National Health Service UK. 8 October 2019. Archived from the original on 31 January 2013. Retrieved 29 January 2020.
  40. "Measles vaccine: Canadian immunization guide". Public Health Agency of Canada. 18 July 2007. Archived from the original on 17 March 2019. Retrieved 13 March 2019.
  41. "Information Sheet: Observed Rate of Vaccine Reactions: Measles, Mumps and Rubella Vaccines" (PDF). World Health Organization (WHO). May 2014. Archived (PDF) from the original on 17 December 2019. Retrieved 1 December 2018.
  42. Di Pietrantonj, Carlo; Rivetti, Alessandro; Marchione, Pasquale; Debalini, Maria Grazia; Demicheli, Vittorio (20 April 2020). "Vaccines for measles, mumps, rubella, and varicella in children". The Cochrane Database of Systematic Reviews. 4: CD004407. doi:10.1002/14651858.CD004407.pub4. ISSN 1469-493X. PMC 7169657. PMID 32309885.
  43. Committee to Review Adverse Effects of Vaccines; Institute Of, Medicine; Stratton, K.; Ford, A.; Rusch, E.; Clayton, E. W. (9 April 2012). "Measles, Mumps, and Rubella Vaccine". Adverse Effects of Vaccines: Evidence and Causality. Washington, D.C.: The National Academies Press. doi:10.17226/13164. ISBN 978-0-309-21436-0. PMID 24624471. Archived from the original on 7 November 2017. Retrieved 3 November 2017.
  44. "Measles, mumps, and rubella (MMR) vaccine". Centers for Disease Control and Prevention. 22 August 2008. Archived from the original on 8 October 2008. Retrieved 21 December 2008.
  45. Institute of Medicine (US) Immunization Safety Review Committee (17 May 2004). Immunization Safety Review: Vaccines and Autism. Institute of Medicine of the National Academy of Sciences. doi:10.17226/10997. ISBN 978-0-309-09237-1. PMID 20669467. Archived from the original on 7 October 2014. Retrieved 19 October 2019.
  46. "Guidelines for Vaccinating Pregnant Women". Centers for Disease Control and Prevention. August 2016. Archived from the original on 6 April 2020. Retrieved 30 April 2019.
  47. "Contraindications and Precautions". Vaccine Recommendations and Guidelines of the ACIP. Centers for Disease Control and Prevention. 23 April 2020. Archived from the original on 1 May 2019. Retrieved 30 April 2019.
  48. "Work by Enders Brings Measles Vaccine License". The Hartford Courant. 22 March 1963. Archived from the original on 3 November 2012. A strain of measles virus isolated in 1954 by Dr. Thomas C. Peebles, instructor in pediatrics at Harvard, and Enders, formed the basis for the development of the present vaccine
  49. Griffin DE (March 2018). "Measles Vaccine". Viral Immunol. 31 (2): 86–95. doi:10.1089/vim.2017.0143. PMC 5863094. PMID 29256824.
  50. "The Measles Vaccine". The New York Times. 28 March 1963. Archived from the original on 30 April 2019. Retrieved 30 April 2019.
  51. Hilleman MR (July 1992). "Past, present, and future of measles, mumps, and rubella virus vaccines". Pediatrics. 90 (1 Pt 2): 149–53. doi:10.1542/peds.90.1.149. PMID 1603640. S2CID 33115842.
  52. Beautysays (27 September 2009). "David Morley - a career of service that started in Nigeria". Nigeria Health Watch. Retrieved 29 April 2022.
  53. Morley DC, Woodland M, Krugman S, Friedman H, Grab B (1964). "Measles and Measles Vaccination in an African Village". Bulletin of the World Health Organization. 30: 733–9. PMC 2554995. PMID 14196817.
  54. Pritchard J (13 November 1997). "Obituary: Dr C. A. Pearson". The Independent. Archived from the original on 24 February 2014. Retrieved 29 January 2014.
  55. Sullivan P (13 April 2005). "Maurice R. Hilleman Dies; Created Vaccines (washingtonpost.com)". The Washington Post. Archived from the original on 20 October 2012. Retrieved 21 July 2009.
  56. Ovsyannikova IG, Johnson KL, Naylor S, Poland GA (February 2005). "Identification of HLA-DRB1-bound self-peptides following measles virus infection". Journal of Immunological Methods. 297 (1–2): 153–67. doi:10.1016/j.jim.2004.12.020. PMID 15777939.
  57. "M-M-R II- measles, mumps, and rubella virus vaccine live injection, powder, lyophilized, for suspension". DailyMed. 24 September 2019. Archived from the original on 6 April 2020. Retrieved 29 January 2020.
  58. "Q&As about Monovalent M-M-R Vaccines". Centers for Disease Control and Prevention (CDC). 26 October 2009. Archived from the original on 19 October 2019. Retrieved 18 October 2019.
  59. Atwood, Alicia (2022). "The Long-Term Effects of Measles Vaccination on Earnings and Employment". American Economic Journal: Economic Policy. 14 (2): 34–60. doi:10.1257/pol.20190509. ISSN 1945-7731. S2CID 248468606.
  60. "M-M-RVaxPro EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 April 2020. Retrieved 29 January 2020.
  61. "Priorix - Summary of Product Characteristics (SmPC)". (emc). 14 January 2020. Archived from the original on 6 April 2020. Retrieved 29 January 2020.
  62. "VFC | Home | Vaccines for Children Program | CDC". www.cdc.gov. 2 April 2019. Archived from the original on 1 May 2020. Retrieved 30 April 2020.
  63. "State Vaccination Requirements | CDC". www.cdc.gov. 11 March 2019. Archived from the original on 2 April 2020. Retrieved 30 April 2020.
  64. "MMR Vaccine Mandates for Child Care and K-12". www.immunize.org. Archived from the original on 12 June 2020. Retrieved 30 April 2020.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.